| Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320) |
|---|
| 12/24/2009 | US20090317822 Selection of intracellular immunoglobulins |
| 12/24/2009 | US20090317808 Novel nucleotide and amino acid sequences and methods of use thereof for diagnosis |
| 12/24/2009 | US20090317409 Antibodies for ubiquitinated proteins |
| 12/24/2009 | US20090317408 Ligand conjugated thermotherapy susceptors and methods for preparing same |
| 12/24/2009 | US20090317406 Phosphorylation of tau by abl |
| 12/24/2009 | US20090317405 Antibody and uses thereof |
| 12/24/2009 | US20090317404 Reduction and prevention of cell-associated hiv transepithelial migration, microbides and other formulations and methods |
| 12/24/2009 | US20090317403 Use of CSF-1 Inhibitors |
| 12/24/2009 | US20090317402 Antibodies to il-6 and their uses |
| 12/24/2009 | US20090317401 Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 |
| 12/24/2009 | US20090317400 Anti-IL 17A/IL-17F Cross-Reactive Antibodies and Methods of Use Thereof |
| 12/24/2009 | US20090317398 a labeled polyclonal antibody, monoclonal antibody or antigen-binding fragment which preferentially binds to a polypeptide that chemoattracts peripheral blood monocytes or T-cells; proteins which control development, differentiation, trafficking and physiology of mammalian cells; immunology |
| 12/24/2009 | US20090317397 Soluble CTLA4 mutant molecules and uses thereof |
| 12/24/2009 | US20090317396 Antibody specifically binding to dr5 and composition for preventing or treating cancers comprising the same |
| 12/24/2009 | US20090317395 Antimicrobial Peptide Derived from Galanin Message Associated Peptide (GMAP) |
| 12/24/2009 | US20090317394 Vascular endothelial growth factor-2 |
| 12/24/2009 | US20090317391 Cancer Related Genes (PTPE) |
| 12/24/2009 | US20090317389 Fusion molecules and methods for treatment of immune diseases |
| 12/24/2009 | US20090317382 Use of effector-function-deficient antibodies for treatment of auto-immune diseases |
| 12/24/2009 | US20090317381 Clearance of abnormal iga1 in iga1 deposition diseases |
| 12/24/2009 | US20090317380 Use of prion conversion modulating agents |
| 12/24/2009 | US20090317379 Autophilic antibodies and method of making the same |
| 12/24/2009 | US20090317368 B7-h1, a novel immunoregulatory molecule |
| 12/24/2009 | US20090317358 Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| 12/24/2009 | US20090317329 Anticoagulation agent and uses thereof |
| 12/24/2009 | US20090314660 Novel Electropolymerisable Monomers, Soluble in an Aqueous Solution and Comprising a Metalloporphyrin |
| 12/23/2009 | WO2009155609A1 IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE |
| 12/23/2009 | WO2009155538A1 Compositions and methods of depleting amyloid-beta peptides from cerebrospinal fluid to treat alzheimer's disease |
| 12/23/2009 | WO2009155513A2 Immunoglobulins with reduced aggregation |
| 12/23/2009 | WO2009155504A2 Methods for the modulation of angiogenesis |
| 12/23/2009 | WO2009155373A1 Nucleotide and protein sequence of guinea pig il-6 and methods of use |
| 12/23/2009 | WO2009155324A2 Pigf-1 assay and kits and components thereof |
| 12/23/2009 | WO2009155180A1 Antibodies to il-6 and their uses |
| 12/23/2009 | WO2009155060A2 Anti-pyk2 antibodies |
| 12/23/2009 | WO2009155015A1 Anti-flt3 antibodies |
| 12/23/2009 | WO2009154565A1 Combination therapies against cancer |
| 12/23/2009 | WO2009154461A1 Use of anti-factors xi antibodies for prevention of thrombus formation |
| 12/23/2009 | WO2009154283A1 Antibody directed against calcified globule, and use thereof |
| 12/23/2009 | WO2009154026A1 Antibody against calcified globule and use of the same |
| 12/23/2009 | WO2009154025A1 ANTIBODY AGAINST OXIDIZED LDL/β2GPI COMPLEX AND USE OF THE SAME |
| 12/23/2009 | WO2009153992A1 Cdca1 epitope peptides and vaccines containing the same |
| 12/23/2009 | WO2009153337A1 Infection inhibitor |
| 12/23/2009 | WO2009153029A1 Anti-prion protein antibody fragment |
| 12/23/2009 | WO2009152901A1 Methods for treatment of malignancies |
| 12/23/2009 | WO2009152783A1 Inhibitors of the epidermal growth factor receptor (egfr) with cytostatic action and their uses in tumour therapy |
| 12/23/2009 | WO2009126817A3 Ige antibodies for the treatment of cancer |
| 12/23/2009 | WO2009100035A3 Interleukin-21 (il-21) and il-21 receptor (il-21r) modulation of regulatory t cells and forkhead box p3 (foxp3) |
| 12/23/2009 | WO2009070648A3 Humanized anti-amyloid beta antibodies |
| 12/23/2009 | WO2009054873A3 Anti-rantes antibodies and methods of use thereof |
| 12/23/2009 | WO2000015247A8 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists |
| 12/23/2009 | EP2135953A1 Novel hemopoietin receptor protein, Nr. 10 |
| 12/23/2009 | EP2135952A2 Cripto antagonism of activin and TGF-beta signaling |
| 12/23/2009 | EP2135947A1 Antagonists of bacterial sequences |
| 12/23/2009 | EP2135881A1 Antibodies binding to the tumour associated antigen TAT10772 for the diagnosis and treatment of tumor |
| 12/23/2009 | EP2135880A1 Anti-prion protein antibody fragment |
| 12/23/2009 | EP2135879A2 Ligand |
| 12/23/2009 | EP2135876A2 Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotherapy |
| 12/23/2009 | EP2135619A1 Humanized anti-CCR2 antibodies and methods of use therefor |
| 12/23/2009 | EP2135087A1 Immunoassay for quantification of an unstable antigen selected from bnp and probnp |
| 12/23/2009 | EP2134841A2 Methods for producing active scfv antibodies and libraries therefor |
| 12/23/2009 | EP2134751A2 Methods of treating ophthalmic diseases |
| 12/23/2009 | EP2134750A1 Ig-pCONSENSUS GENE VACCINATION PROTECTS FROM ANTIBODY-DEPENDENT IMMUNE PATHOLOGY IN AUTOIMMUNE DISEASE |
| 12/23/2009 | EP2134749A2 Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| 12/23/2009 | EP2134746A1 Monoclonal human tumor-specific antibody |
| 12/23/2009 | EP2134366A2 Products for prophylaxis and/or treatment of viral diseases and method of making and using same |
| 12/23/2009 | EP2134356A2 Negative genetic regulation of cancer cell renewal in synergy with notch- or numb-specific immunotherapy |
| 12/23/2009 | EP1483297B1 Antibodies derived from anti ed-b l19 and targeting tumor vasculature |
| 12/23/2009 | EP1290028B1 A GENE ENCODING A MULTIDRUG RESISTANCE HUMAN P-GLYCOPROTEIN HOMOLOGUE ON CHROMOSOME 7p15-21 AND USES THEREOF |
| 12/23/2009 | CN101611318A Biomarkers |
| 12/23/2009 | CN101611060A Intranasal delivery of polypeptides and proteins |
| 12/23/2009 | CN101611059A Antibodies against insulin-like growth factor I receptor and uses thereof |
| 12/23/2009 | CN101611058A PRLR-specific antibody and uses thereof |
| 12/23/2009 | CN101611057A Antibody molecules for human il-17 |
| 12/23/2009 | CN101611056A Peptides capable of binding to serum proteins |
| 12/23/2009 | CN101611055A Human antibodies to human DELTA like ligand 4 |
| 12/23/2009 | CN101611054A Humani zed antibody against amyloid beta |
| 12/23/2009 | CN101608182A Oncogene, recombinant protein derived therefrom, and uses thereof |
| 12/23/2009 | CN101607995A Monoclonal antibody or binding activity fragment thereof of H5 subtype avian influenza virus hemagglutinin protein and application thereof |
| 12/23/2009 | CN101607994A Preparation method for duck viral hepatitis refine yolk antibody |
| 12/23/2009 | CN101607985A Monoclonal antibody for anti-human CEA, a composition containing same and application thereof |
| 12/23/2009 | CN100572535C Specifically expressed gene in dopamine-producing neuron precursor cells after termination of division |
| 12/23/2009 | CN100572395C Synthesis process of olaquindox artificial antigen |
| 12/23/2009 | CN100572392C 截短tau蛋白 Truncated tau protein |
| 12/23/2009 | CN100571785C Relativity between AnnexinA3 and drug resistance of platinum type chemical curing medication for cancer |
| 12/23/2009 | CA2728473A1 Antibody against oxidized ldl/.beta.2gpi complex and use of the same |
| 12/23/2009 | CA2728276A1 Combination therapies against cancer |
| 12/23/2009 | CA2728268A1 Cdca1 epitope peptides and vaccines containing the same |
| 12/23/2009 | CA2728120A1 Pigf-1 assay and kits and components thereof |
| 12/23/2009 | CA2727937A1 Immunoglobulins with reduced aggregation |
| 12/23/2009 | CA2727909A1 Anti-prion protein antibody fragment |
| 12/23/2009 | CA2726522A1 Anti-flt3 antibodies |
| 12/23/2009 | CA2724257A1 Antibodies to il-6 and their uses |
| 12/22/2009 | US7635767 Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same |
| 12/22/2009 | US7635766 Insulin-responsive DNA binding proteins-1 and methods to regulate insulin-responsive genes |
| 12/22/2009 | US7635760 Having high affinity and may be chimeric, humanized or fully human antibodies, immunoconjugates of the antibodies or antigen-binding fragments thereof; useful for increasing muscle mass, increasing bone density, or for the treatment of various disorders in mammalian and avian species |
| 12/22/2009 | US7635759 Gene encoding labyrinthin, a marker for cancer |
| 12/22/2009 | US7635758 Immunoglobulin for use in diagnosis of metabolic, glandular, cell proliferative, gastroitestinal amd reproductive disorders |
| 12/22/2009 | US7635757 Nucleotide sequence which hybridizes to the complement of the specific nucleic acid molecule over its full length under conditions of incubation and encodes a polypeptide which costimulates T cell proliferation in vitro |
| 12/22/2009 | US7635749 Methods and compositions for prolonging elimination half-times of bioactive compounds |
| 12/22/2009 | US7635687 Vector system |